Literature DB >> 29567794

Early OCT angiography changes of type 1 CNV in exudative AMD treated with anti-VEGF.

Luisa Frizziero1, Anna Rita Daniele2, Elisabetta Pilotto2, Enrica Convento2, Evelyn Longhin2, Francesca Guidolin2, Raffaele Parrozzani2, Fabiano Cavarzeran2, Edoardo Midena2,1.   

Abstract

AIMS: To investigate, with optical coherence tomography angiography (OCTA), short-term changes of type 1 choroidal neovascularisation (CNV), secondary to exudative age-related macular degeneration, after anti-vascular endothelial growth factor (VEGF) treatment.
METHODS: Patients affected by type 1 CNV treated with intravitreal anti-VEGF were consecutively enrolled. All patients underwent OCTA examination before and 48 hours after anti-VEGF treatment. Quantitative and qualitative vascular and morphological macular changes were evaluated.
RESULTS: Sixteen eyes were included (11 treated with aflibercept and 5 with ranibizumab). Both CNV mean area and pigment epithelium detachment significantly reduced (p=0.0004 and p=0.0007, respectively) after treatment. Cystoid macular oedema (four eyes) decreased in all cases. Neuroretinal detachment (13 eyes) decreased in 85% of cases (11 eyes). Fine CNV vessels density decreased in 75% (12 eyes), whereas larger CNV vessels density remained stable in 66.7% (10 eyes), choroidal flow void signal (7 eyes at baseline) increased in 42.9% (3 eyes) of them and remained stable in 57.1% (4 eyes). Interoperator reproducibility for OCT examination was good for all measurements (intraclass correlation coefficient>0.65).
CONCLUSION: Early remodelling of type 1 CNV network after treatment may be non-invasively and reproducibly analysed by means of OCTA. Choroidal perfusion impairment, choroidal flow void signal, surrounding CNV may change during treatment. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  imaging; macula; neovascularisation; retina; treatment other

Mesh:

Substances:

Year:  2018        PMID: 29567794     DOI: 10.1136/bjophthalmol-2017-311752

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  9 in total

1.  Assessment of three successive treatments of ranibizumab on neovascular macular degeneration by OCT angiography.

Authors:  Juming Zhu; Qing Peng; Tu Su; Minli Wang; Fang Wang
Journal:  Exp Ther Med       Date:  2020-11-19       Impact factor: 2.447

2.  A proof of concept study to evaluate the treatment response of aflibercept in wARMD using OCT-A (Canada study).

Authors:  Simrat K Sodhi; Carmelina Trimboli; Sivaruben Kalaichandran; Austin Pereira; Netan Choudhry
Journal:  Int Ophthalmol       Date:  2021-02-07       Impact factor: 2.031

3.  Supercontinuum source-based multi-contrast optical coherence tomography for rat retina imaging.

Authors:  Jia-Pu Syu; Waradee Buddhakosai; Shih-Jen Chen; Chang-Chih Ke; Shih-Hwa Chiou; Wen-Chuan Kuo
Journal:  Biomed Opt Express       Date:  2018-11-12       Impact factor: 3.732

4.  Nonexudative morphologic changes of neovascularization on optical coherence tomography angiography as predictive factors for exudative recurrence in age-related macular degeneration.

Authors:  Han Joo Cho; Jaemin Kim; Seung Kwan Nah; Jihyun Lee; Chul Gu Kim; Jong Woo Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-09-13       Impact factor: 3.117

5.  Vascular density in age-related macular degeneration after one year of antiVEGF treatment with treat-and-extend and fixed regimens.

Authors:  Miklós D Resch; Anikó Balogh; Gábor Gy Deák; Zoltán Z Nagy; András Papp
Journal:  PLoS One       Date:  2020-02-26       Impact factor: 3.240

6.  Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting.

Authors:  Anne Rübsam; Saskia Rau; Daniel Pilger; Oliver Zeitz; Antonia M Joussen
Journal:  J Ophthalmol       Date:  2022-03-25       Impact factor: 1.909

7.  Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatment.

Authors:  Henrik Faatz; Marie-Louise Farecki; Kai Rothaus; Matthias Gutfleisch; Daniel Pauleikhoff; Albrecht Lommatzsch
Journal:  BMJ Open Ophthalmol       Date:  2019-12-10

8.  Longitudinal Analysis of the Choriocapillaris Using Optical Coherence Tomography Angiography Reveals Subretinal Fluid as a Substantial Confounder in Patients with Acute Central Serous Chorioretinopathy.

Authors:  Michael Reich; Daniel Böhringer; Bertan Cakir; Felicitas Bucher; Moritz Daniel; Stefan Lang; Wolf Lagrèze; Hansjürgen Agostini; Clemens Lange
Journal:  Ophthalmol Ther       Date:  2019-10-25

9.  Prospective Study of Vessel Density by Optical Coherence Tomography Angiography After Intravitreal Bevacizumab in Exudative Age-Related Macular Degeneration.

Authors:  Gilda Cennamo; Daniela Montorio; Anna D'Alessandro; Pasquale Napolitano; Luca D'Andrea; Fausto Tranfa
Journal:  Ophthalmol Ther       Date:  2019-10-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.